On TED, Roger Stein, a chief analytics officer at State Global exchange and a senior lecturer in finance at MIT Sloan, presented an interesting new model about financing biomedical research. Essentially, early stage biomedical research is pooled together and funding into a single fund. If one idea out of a hundred is financially successfully, then one successful idea will fund the other technologies. This setup is similar to VC, but this setup will fund earlier stage technologies. Stein's idea is different and quite innovative. The idea is using a new funding scheme to push innovation and help people. This is basically a securitization structure of financing.
This scheme is unlike the current funding schemes for biotechnologies. Each research technology has to go through each of their own process of finding funds. Venture capital will fund at advanced clinical development, but VC will stay away from early stage ideas.
There are several questions that need to be answered before embark a totally radical funding scheme.
If you are adventurous, you can read the idea in Nature Biotechnology and the Economist.
Original paper: Nature Biotechnology, The Economist
- This scheme assumes a percentage of concepts make it into the market and become successful. What is the threshold for this scheme to become successful?
- This is a scheme similar to that of the mortgage-backed securitization, which was partly responsible for the recent financial crisis. How does biotechnology secrutization avoid problems that the mortgage-backed securitization faced?
- What is the necessary funding required to start a fund? Funding biomedical research is highly capital driven.
- In what way are biomedical researchers involved? Researchers should have input into what concepts get funding.
If you are adventurous, you can read the idea in Nature Biotechnology and the Economist.
Original paper: Nature Biotechnology, The Economist
